Adam Gridley, Allay Therapeutics CEO
A non-opioid pain startup believes it can top the bupivacaine market — and it's thinking in terms of weeks, not days
The road to non-opioid pain management has swallowed biotech players for years as drug developers have smacked their heads against safety flags. A California biotech that spent a long time working in stealth mode now has early data suggesting it may have found a breakthrough — and the company is ready for its close-up.
Allay Therapeutics launched Thursday with Phase I data showing their polymerized bupivacaine implant helped 80% of patients get off opioids 14 days after a total knee replacement, the company said.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters